Kamada (KMDA) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kamada Ltd. has announced robust financial results for the first half of 2024, showing an 18% increase in six-month revenue and a significant 68% rise in profitability. The strong performance, driven by increased sales of FDA-approved products and successful market penetration in the U.S., has led the company to reiterate its full-year revenue guidance of $158 million to $162 million, with an adjusted EBITDA forecast of $28 million to $32 million. Cash flow from operating activities also reflected positive growth, reinforcing the company’s financial health.
For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.
